Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 121Lymphoma, Mantle-Cell 68Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Non-Hodgkin 31Lymphoma, Follicular 30Waldenstrom Macroglobulinemia 29Lymphoma 29Recurrence 23Lymphoma, B-Cell 22Lymphoma, B-Cell, Marginal Zone 19Neoplasms 16Leukemia 14Leukemia, B-Cell 10Multiple Myeloma 9Bronchiolitis Obliterans Syndrome 9Leukemia, Lymphoid 8Burkitt Lymphoma 8Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hodgkin Disease 5Leukemia, Prolymphocytic 4Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Hairy Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Chromosome 17 deletion 3

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 4venetoclax 3ruxolitinib 3Cytarabine 3Alemtuzumab 3itacitinib 2duvelisib 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Carmustine 2thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1ibrutinib 1Tacrolimus 1Sensitivity and Specificity 1Mitoxantrone 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × ibrutinib × Clear all
NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

AbbVie

Phase 2 Completed
14 enrolled 19 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡